IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#4846
Positioning
Market Dominance
Manufacturing
Medical Equipment
$36M
Adam Sachs
Vicarious Surgical Inc. engages in developing and selling single-incision surgical robot that virtually transports surgeons inside the patient to perform minimally invasive surgery. The company was incorporated in 2014 and is headquartered in Waltham, Massachusetts.
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | 28.5% | 8.0% | 100.0% | 100.0% | 10.4% | -4.6% | 3.3% | 0.0x | $141.8B | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | 46.1% | 16.6% | 51.3% | 31.9% | 26.8% | -4.0% | 1.0% | 25.0x | $272.1B | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | 10.3% | 3.1% | 24.1% | 7.2% | 4.7% | 14.3% | 0.8% | 25.0x | $11.4B | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | 2.2% | 1.5% | 9.3% | 5.3% | 2.2% | -8.5% | 2.2% | 16.0x | $18.9B | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 35.5% | 19.8% | 48.7% | 29.2% | 24.7% | 4.4% | 0.8% | 32.0x | $181.9B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | 11.8% | 8.8% | 45.9% | 11.3% | 11.1% | 25.7% | 3.7% | 0.0x | $1.8B | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.6% | 7.0% | 66.5% | 17.1% | 15.6% | 39.0% | 0.0% | 0.0x | $115M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | 22.6% | 4.9% | 71.2% | 12.8% | 9.4% | 1.7% | 5.9% | 124.0x | $72.1B | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | 3.0% | 1.1% | 20.9% | 7.3% | 1.3% | 3.0% | 0.9% | 67.0x | $1.2B | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | 8.2% | 3.5% | 55.3% | 25.9% | 12.4% | 0.7% | 1.7% | 0.0x | $87.0B | VS | |
$RBOT Vicarious Surgical Inc. | 20 | 14 | 13 | 4 | - | - | -402.9% | -193.4% | - | - | - | - | 0.0% | 108.0x | $36M | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -2.5% | -0.1% | 42.5% | 1.3% | -0.2% | 5.9% | 0.0% | 0.2x | - | REF |
Vicarious Surgical Inc. (RBOT) receives a "Avoid" rating with a composite score of 20.2/100. It ranks #4846 out of 7,333 stocks in our coverage universe and carries a 1-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
Equity capital efficiency
Asset base utilization
Financial leverage load
Direct cash return
Adam Sachs
Chief Executive Officer
Labor Force
210
14
25
17
Audit Verdict: Lower quality and stability scores may indicate governance concerns.
No recent insider transactions available for RBOT
Lagging peers — losers tend to keep underperforming
Expensive relative to fundamentals — limited margin of safety
Weak fundamentals — higher risk of value trap
High volatility — wider range of outcomes increases timing risk
Aggressive spending — empire-building risk, dilutive growth
Below-average composite — caution warranted
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
No analyst ratings for RBOT.
View All RatingsInsufficient data for Financial Analysis
ROIC -108.6% vs WACC 7.3% (spread -116.0%)
GM N/A vs sector 43%, OM N/A vs sector 1%
Capital turnover 0.00x
Rev growth N/A, 5yr history
Interest coverage N/A
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
Our quantitative model flags Vicarious Surgical Inc. with an Avoid rating, assigning a composite score of 20.2/100 and 1 out of 5 stars. Ranked #4846 of 7,333 stocks, RBOT falls in the bottom tier across key factors. Historically, stocks with this profile have faced elevated risk of underperformance and capital loss.
Vicarious Surgical Inc. registers a weak quality score of just 14/100, indicating significant profitability challenges. The company reports a return on equity of -402.9% (sector avg: -2.5%). Low quality scores are often associated with businesses in turnaround mode, early-stage growth, or structurally challenged industries.
RBOT registers a value score of just 13/100, suggesting the stock trades at a significant premium to its fundamental metrics. Key valuation metrics include a P/B ratio of 1.14x. High-premium valuations like this require strong future execution to avoid multiple compression, and downside risk is elevated if growth disappoints.
Vicarious Surgical Inc.'s investment score of 25/100 suggests limited reinvestment activity. Key growth metrics include a return on assets of -193.4% (sector: -0.1%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.
Vicarious Surgical Inc. is experiencing notably weak momentum with a score of just 4/100. The stock has underperformed its peers and is trending below major moving averages. Revenue growth data is not currently available, while a beta of 1.84 reflects its sensitivity to broader market moves. While deep momentum weakness can occasionally present value opportunities, it often reflects deteriorating fundamentals or structural headwinds that may persist.
Vicarious Surgical Inc. registers a low stability score of 17/100, indicating high volatility and potentially stressed financial conditions. Key stability metrics include a beta of 1.84 and a debt-to-equity ratio of 108.00x (sector avg: 0.2x). Stocks at this level carry elevated capital loss risk and may be unsuitable for conservative portfolios without careful risk management.
The short interest score of 51/100 for RBOT suggests somewhat elevated bearish positioning by institutional traders. Specific risk factors include high market sensitivity (beta: 1.84), elevated leverage (D/E: 108.00x), micro-cap liquidity risk. With a $36M market cap (micro-cap), Vicarious Surgical Inc. may experience above-average volatility. Investors should consider whether the short thesis has merit or if it creates a potential short-squeeze opportunity.
Vicarious Surgical Inc. is a micro-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #4846 of 7,333 overall (34th percentile). Key comparisons include ROE of -402.9% trailing the -2.5% sector median. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While RBOT currently exhibits a AVOID profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Upgrade catalyst
Improvement in Momentum (4) would have the largest impact on the composite score.
ROE 16145% ABOVE SECTOR MEDIAN (FAVORABLE)
Debt/Equity 53900% ABOVE SECTOR MEDIAN
Div. Yield NaN% BELOW SECTOR MEDIAN
AUDIT DATA AS OF SEP 30, 2025 (Q2 FY2025)
We rate Vicarious Surgical Inc. (RBOT) as Avoid with a composite score of 20.2/100 at a current price of $2.02. The stock falls in the bottom quintile of our universe across key quantitative factors, and the multi-factor weakness suggests a high probability of continued underperformance.
The rating is primarily driven by strength in investment (25th percentile) and stability (17th percentile), which together account for the majority of the composite score. Offsetting weakness in momentum (4th percentile) and value (13th percentile) tempers our overall conviction. We assign a No Moat rating (18/100), Very High uncertainty, and Poor capital allocation.
Key items to watch: momentum to confirm whether the current price trend has legs; balance sheet deleveraging progress; valuation compression risk if growth disappoints. Any material change in these dynamics could warrant a reassessment of our rating. The moat trend is stable, which suggests the competitive landscape is stable for now.
Vicarious Surgical Inc. holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 20.2/100 places it at rank #4846 in our full 7,333-stock universe. At $36M in market capitalization, Vicarious Surgical Inc. is a small-cap player in the Manufacturing space, which limits certain scale advantages but may allow for more agile strategic execution.
Momentum indicators (4th percentile) suggest caution regarding the near-term price trend. Revenue growth data is unavailable, limiting our ability to confirm whether momentum is fundamentally supported.
Margin data is not available for Vicarious Surgical Inc., which limits our assessment of the company's cost structure and operating efficiency. We rely on factor-based signals to infer business quality in the absence of detailed margin data.
At a current price of $2.02, Vicarious Surgical Inc. is trading at a premium to fundamental value. Our value factor score of 13/100 reflects a composite assessment across multiple valuation metrics including price-to-earnings, price-to-book, EV/EBITDA, and price-to-sales ratios relative to both sector peers and the broader market. The premium valuation implies the market is pricing in significant future growth or quality improvements that are not yet fully reflected in current fundamentals.
The stock currently trades at P/B of 1.1x. We evaluate these multiples in the context of both absolute levels and sector-relative positioning to form our valuation view.
The stock may offer contrarian value if near-term headwinds prove transitory — the current weakness in factor scores may reverse if business fundamentals stabilize.
The Avoid rating (composite 20.2/100) reflects multi-factor weakness, and historically, stocks in this scoring range have underperformed the market by a meaningful margin.
Elevated leverage (108% D/E) amplifies downside risk and limits management's financial flexibility in adverse scenarios.
Weak momentum (4th percentile) suggests institutional selling pressure and unfavorable technical dynamics that may persist.
Below-average quality (14th percentile) raises durability concerns about the fundamental profile and increases the risk of negative earnings surprises.
We assign a Very High uncertainty rating to Vicarious Surgical Inc.. The stock exhibits multiple compounding risk factors: elevated market sensitivity (beta of 1.84), significant leverage (108% debt-to-equity), below-average price stability (17th percentile). The extreme uncertainty around future cash flows makes precise valuation difficult, and the range of outcomes is exceptionally wide. Only investors with high risk tolerance and extended time horizons should consider this name.
Specific risk factors that inform our assessment include: elevated market sensitivity (beta of 1.84); significant leverage (108% debt-to-equity); below-average price stability (17th percentile); weak quality scores (14th percentile). Each of these factors independently widens the distribution of potential outcomes, and in combination they create a risk profile that demands careful position sizing. The stability factor at the 17th percentile and quality factor at the 14th percentile provide a quantitative summary of the overall risk landscape.
We identify limited risk mitigants at this time, which contributes to our very high uncertainty assessment. Investors should monitor for improvement in balance sheet metrics, margin stability, and business predictability that could warrant a downgrade in our risk assessment over time.
We rate Vicarious Surgical Inc.'s capital allocation as Poor. Key concerns include low returns on equity (-402.9%), weak asset returns (ROA -193.4%). Exemplary capital allocators generate ROE above 20% and maintain conservative leverage — Vicarious Surgical Inc. significantly underperforms these benchmarks, raising questions about management's ability to create shareholder value.
Investors should scrutinize management's reinvestment decisions and balance sheet trajectory before committing capital. Poor capital allocation often compounds over time: overlevered balance sheets limit strategic flexibility, while low returns on capital destroy shareholder value. We would need to see sustained improvement in profitability metrics and balance sheet discipline before considering an upgrade.
In summary, Vicarious Surgical Inc. receives a Avoid rating with a composite score of 20.2/100 (rank #4846 of 7,333). Our quantitative framework assigns a No Moat (18/100, trend: stable), Very High uncertainty, and Poor capital allocation. The average factor score across quality, value, momentum, stability, and investment is 15/100.
Our analysis does not support a constructive view on Vicarious Surgical Inc. at this time. The combination of limited competitive advantages, very high uncertainty, and poor capital allocation suggests unfavorable risk-reward at current levels. We recommend investors avoid new positions and existing holders consider reducing exposure.
Analysis derived from Blank Capital Research quantitative terminal. For informational purposes only. No trade solicitation. Past performance not indicative of future results. Consult a qualified advisor.
We do not assign Vicarious Surgical Inc. a meaningful economic moat, scoring 18/100 on our composite assessment. The ROIC-WACC spread of -116.0% is the primary signal of economic value creation. Current fundamentals do not demonstrate the kind of durable competitive advantages — such as superior returns on invested capital, margin superiority, or reinvestment efficiency — that would protect the company from competitive erosion over the long term. The highest-scoring pillar, margin superiority, reached only 10/20.
The strongest moat sources are margin superiority (10/20) and financial resilience (5.7/20). GM N/A vs sector 43%, OM N/A vs sector 1%. Interest coverage N/A. These pillars form the core of Vicarious Surgical Inc.'s competitive identity and are the primary drivers of excess returns in our framework.
Areas of relative weakness include reinvestment efficiency (0/20) and growth durability (0/20). Capital turnover 0.00x. Improvement in these areas could meaningfully widen the moat over time, while deterioration would be an early warning of competitive erosion.
Our moat trend assessment is Stable. Multi-year ROIC and operating margin trajectories show neither meaningful improvement nor deterioration, suggesting the competitive position is steady. We expect Vicarious Surgical Inc.'s moat profile to remain largely unchanged absent a material shift in return on capital or industry dynamics.
Key profit drivers are not clearly identifiable from current fundamentals. This may reflect a company in transition, a cyclical downturn, or structural challenges in the business model. We assign a quality factor of 14/100 which further underscores our concern regarding earnings sustainability.
Return metrics include ROE of -402.9% and ROA of -193.4%. Relative to the Manufacturing sector, sector comparison data is limited, and ROE of -402.9% compares to a sector median of -2.5%.
The balance sheet reflects above-average leverage with D/E of 108%. The sector median D/E is 0%, putting Vicarious Surgical Inc. at higher leverage than the typical peer. Overall balance sheet health is adequate for the current business environment.
High beta of 1.84 means amplified losses in market selloffs — in a broad market correction, this stock would likely decline more than the index.
Above 50MA
37.18%
Net New Highs
+51081
Shares of SOPHiA GENETICS SA (NASDAQ: SOPH) fell sharply during Tuesday’s session after the company reported worse than expected fourth-quarter earnings and issued 2024 guidance. Sophia Genetics posted GAAP loss of 37 cents per share, versus market expectations for a loss of 27 cents per share. The company’s quarterly sales came in at $17.05 million, missing estimates of $17.33 million. SOPHiA GENETICS shares tumbled 19% to $4.55 on Tuesday. Here are some other stocks moving in today's mid-day session. Gainers Sunshine Biopharma, Inc. (NASDAQ: SBFM) climbed 146.3% to $0.1106 after dipping 19% on Monday. Sunshine Biopharma recently announced closing of $10.0 million underwritten public offering. Airship AI Holdings, Inc. (NASDAQ: AISP) climbed 93.3% to $3.16 after the company announced that it has been awarded a contract with the Department of Justice for its Acropolis Enterprise Sensor Management video and data management platform. Bruush Oral Care Inc. (NASDAQ: BRSH) surged 42.9% to $0.0686. Apogee Therapeutics, Inc. (NASDAQ: APGE) shares jumped 41.6% to $59.10 after the company announced interim results from its Phase 1 healthy volunteer trial for APG777. Also, the company reported FY23 financial results. Dave Inc. (NASDAQ: DAVE) gained 39.8% to $30.62 after the company reported a year-over-year increase in fourth-quarter revenue results. CareMax, Inc. (NASDAQ: CMAX) rose 38.1% to $10.65. Enviva Inc. (NYSE: EVA) gained 26.4% to $0.6571. AeroVironment, Inc. (NASDAQ: AVAV) shares surged 24.8% to $163.05 after the company reported better-than-expected results for its fourth quarter. The company said it sees FY24 adjusted earnings of $2.69 to $2.83 per share on revenue of $700 million to $710 million. INNOVATE Corp. (NASDAQ: VATE) rose 24.4% to $0.90. The company reported fourth quarter financial results. Ocean Biomedical, Inc. (NASDAQ: OCEA) climbed 24.3% to $5.07. Paymentus Holdings, Inc. (NYSE: PAY) rose gained 20.3% to $19.67 after the company reported better-than-expected fourth quarter financial results. BeyondSpring Inc. (NASDAQ: BYSI) gained 20.1% to $1.97. bioAffinity Technologies, Inc. (NASDAQ: BIAF) climbed 19.4% to $2.83. bioAffinity Technologies reported accelerating sales growth of CyPath® Lung. XORTX Therapeutics Inc. (NASDAQ: XRTX) gained 18.4% to $4.18. Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO) ...
Shares of Paymentus Holdings, Inc. (NYSE: PAY) rose sharply in today’s pre-market trading after the company reported better-than-expected fourth quarter financial results. Paymentus reported quarterly earnings of 11 cents per share which beat the analyst consensus estimate of 7 cents per share. Quarterly sales clocked in at $164.8 million which beat the analyst consensus estimate of $157.416 million. Paymentus Holdings shares jumped 18.3% to $19.34 in pre-market trading Here are some other stocks moving in pre-market trading. Gainers Zhongchao Inc. (NASDAQ: ZCMD) gained 79.8% to $5.70 in pre-market trading. Zhongchao recently announced a 1-for-10 share consolidation. Momentus Inc. (NASDAQ: MNTS) shares rose 46.2% to $1.14 in pre-market trading after the company was awarded a contract from NASA. Phunware, Inc. (NASDAQ: PHUN) shares rose 30.2% to $16.16 in pre-market trading. Phunware shares jumped 75% on Monday amid volatility in Trump-related stocks after Donald Trump won the Missouri and Idaho Republican caucuses. Also, the Supreme Court ruled that Colorado can't remove Donald Trump from the Republican primary ballot in the state. Sunshine Biopharma, Inc. (NASDAQ: SBFM) gained 19.3% to $0.0536 in pre-market trading after dipping 19% on Monday. Sunshine Biopharma recently announced closing of $10.0 million underwritten public offering. AeroVironment, Inc. (NASDAQ: AVAV) shares surged 19.1% to $155.50 in ...
Shares of Beyond Meat, Inc. (NASDAQ: BYND) rose sharply in today’s pre-market trading as the company reported stronger-than-expected sales for its fourth quarter. Beyond Meat said fourth-quarter revenues decreased 7.8% year-over-year to $73.7 million, which beat consensus estimates of $66.66 million. The plant-based meat company reported a fourth-quarter loss of $2.40 per share, versus a loss of $1.05 per share in the prior year’s quarter. The company expects full-year 2024 revenues to be between $315 million and $345 million. Beyond Meat shares jumped 56% to $11.73 in pre-market trading Here are some other stocks moving in pre-market trading. Gainers Nauticus Robotics, Inc. (NASDAQ: KITT) gained 80% to $0.55 in pre-market trading. Bit Brother Limited (NASDAQ: BETS) shares rose 68.7% to $4.20 in pre-market trading. Avalon GloboCare Corp. (NASDAQ: ALBT) shares surged 33.4% to $0.4950 in pre-market trading after dipping 8% on Tuesday. Flywire Corporation (NASDAQ:
Shares of Palantir Technologies Inc. (NYSE: PLTR) rose sharply during today’s pre-market trading after the company reported better-than-expected fourth-quarter sales results and issued guidance. Palantir said fourth-quarter revenue increased 20% year-over-year to $608 million, which beat the consensus estimate of $602.41 million, according to Benzinga Pro. Palantir reported quarterly adjusted earnings of 8 cents per share, which was in line with analyst estimates. Palantir expects first-quarter revenue to be between $612 million and $616 million versus estimates of $617.21 million. First-quarter adjusted income from operations is expected to be between $196 million and $200 million. Palantir Technologies shares jumped 18.2% to $19.77 in pre-market trading Here are some other stocks moving in pre-market trading. Gainers InVivo Therapeutics Holdings Corp. (NASDAQ: NVIV) gained 54.2% to $0.3424 in pre-market trading after dipping around 26% on Monday. Chenghe Acquisition Co. (NASDAQ: CHEA) shares jumped 43.2% to $10.08 in pre-market trading. Chenghe Acquisition shares jumped 28% on Monday after shareholders on Friday voted to approve the merger agreement with Taiwan Color Optics, Inc. Exicure, Inc. (NASDAQ: XCUR) gained 36.2% to $0.75 ...
Shares of WD-40 Company (NASDAQ: WDFC) rose sharply during Wednesday’s session after the company reported better-than-expected first-quarter results. WD-40 reported quarterly earnings of $1.28 per share which exceeded the analyst consensus estimate of $1.05 per share. The company reported quarterly sales of $140.42 million, clocking in above the Street's estimate of $134.37 million. WD-40 shares jumped 17.3% to $277.56 on Wednesday. Here are some other stocks moving in today's mid-day session. Gainers Nauticus Robotics, Inc. (NASDAQ: KITT) climbed 87.8% to $0.5501. Nauticus Robotics secured additional funding and appointed John W. Gibson, Jr as interim CEO. Clearmind Medicine Inc. (NASDAQ: CMND) shares jumped 47.7% to $3.0570. Clearmind Medicine completed a Type A Meeting with the FDA for clinical trial of its proprietary MEAI-based, CMND-100 compound, for the treatment of alcohol use disorder. Sana Biotechnology, Inc. (NASDAQ: SANA) gained 46.8% to $7.57. Sana Biotechnology recently announced FDA clearance of investigational new drug application for SC262. Ucommune International Ltd (NASDAQ: UK) jumped 37.8% to $4.98. Vicarious Surgical Inc. (NASDAQ: RBOT) rose 37% to $0.6851. Nvni Group Limited (NASDAQ: NVNI) climbed 35.2% to $2.6091. EchoStar Corporation (NASDAQ: SATS) gained 31% to $16.50. EchoStar completed merger with DISH Network Corporation. Amarin Corporation plc (NASDAQ: AMRN) climbed 28.8% to $1.25 after the company reported strong preliminary FY23 total revenues. Exicure, Inc. (NASDAQ: XCUR) shares rose 17% to $0.5501. Exicure was granted broad U.S. patent #11866700 for "Liposomal Nucleic Acid Constructs Presenting Antisense Oligonucleotides For Knockdown Of Interleukin ...